News

Month Year

Aruvant Announces Data Presentation on Lead Program ARU-1801 at European Hematology Association (EHA) 2021 Virtual Congress

May 12, 2021

--Data suggest individualized melphalan dosing prior to ARU-1801 infusion may improve patient outcomes--
Aruvant's Eleven New Hires Advance its Internal-External Supply Model Strategy to Manufacture Gene Therapies for Rare Diseases

May 4, 2021
Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting

Apr 27, 2021

--Data demonstrates treatment with ARU-1801 resulted in meaningful improvements in clinical outcomes for participants with severe sickle cell disease--
Aruvant Appoints Meghan Kelton Executive Director of Human Resources and E. Blair Clark-Schoeb Senior Vice President of Communications

Apr 23, 2021
Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March

Feb 11, 2021
Aruvant Announces the European Medicines Agency (EMA) Granted Priority Medicines (PRIME) Designation to ARU-1801 for the Treatment of Sickle Cell Disease

Feb 3, 2021
Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trial

Jan 18, 2021
Aruvant's Data Presented in Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Demonstrates Promise of ARU-1801 as a Potentially Curative Treatment for Sickle Cell Disease

Dec 7, 2020

--Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile--
Aruvant to Participate in SVB Leerink's Biopharma Private Company Connect December 15 to 17

Dec 1, 2020
Aruvant Receives Orphan Designation from European Medicines Agency for Gene Therapy ARU-1801 for Sickle Cell Disease

Nov 16, 2020

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa